How were the pharma players impacted?
Buyer’s consolidation has impacted the regular generics businesses
Faster drug approvals have kept up pricing pressure for pharma firms
Regulators are becoming ever-more stringent with increased scrutiny on pricing actions
Notes:
How did PEL perform?
PEL had strategically chosen to stay ahead of the curve and expanded into niche specialty businesses
Hence, PEL’s Pharma business delivered consistent performance, with improving revenues and steady profitability
Significant improvement in Global Pharma EBITDA over the last few years
Note: 1. Pharma revenues include Global Pharma and India Consumer Products